Follicle-stimulating hormone (FSH) plays a central role in mammals reproduction, with the actions of FSH mediated by follicle-stimulating hormone receptors (FSHRs) on the surface of target cells. The purposes of this ...Follicle-stimulating hormone (FSH) plays a central role in mammals reproduction, with the actions of FSH mediated by follicle-stimulating hormone receptors (FSHRs) on the surface of target cells. The purposes of this study were to determine and evaluate the biological activities for the commercialization of recombinant follicle-stimulating hormone (rFSH) in vitro through the cellular internalization using cloned 293T-FSHR cell lines as target. Using imaging approaches we have found here that a little fluorescent signal from the surface of the cell transferred to the cytoplasm and accumulated around the nucleus by endocytosis. Compared with the control groups, the commercialization of rFSH have not the significant differences of internalization, but the rFSH have promoted the internalization of the fluorescent, suggested that this detection system might as a protocol for the bioactivity of recombinant therapeutic proteins in vitro.展开更多
Objective To investigate the difference in the outcome of IVF-ET between the patients using recombinant FSH versus highly purified urinary FSH for controlled ovarian stimulation （COH）. Methods A comparative retrospe...Objective To investigate the difference in the outcome of IVF-ET between the patients using recombinant FSH versus highly purified urinary FSH for controlled ovarian stimulation （COH）. Methods A comparative retrospective analysis was performed between the patients undergoing IVF using recombinant FSH （rFSH） 562 cycles （rFSH group） versus using highly purified urinary FSH（uFSH） 555 cycles （uFSH group） for COH from August 2009 to July 2010. Main outcome measures included： duration of stimulation, total amount of FSH, E2 level on hCG injection day, number of oocytes collected, average number of frozen embryos, and the rate of cancellation, implantation, clinical pregnancy and miscarriage rate. Results uFSH group required a significantly higher total amount of FSH and a longer duration of stimulation than thouse rFSH group （19.3 ± 7.6 vs 18.3 ± 7.0 ampoules, P=0.02, and 9.1 ± 1.6 d vs 8.9 ± 1.5 d, P=0.04, respectively）. There was no statistically significant difference in the implantation rate, clinical pregnancy rate and miscarriage rate between uFSH and rFSH groups （22.57% vs 20.16%, 38.15% vs 35.18%, and 10.6% vs 13.45%, respectively, P〉0.05）. The other measures including E2 level on hCG injection day, cancellation, number of oocytes collected, fertilization, average number of frozen embryos showed no difference between the two groups. Conclusion There is no significant difference in the outcome of IVF-ET between two groups in effects of recombinant FSH versus highly purified urinary FSH for COH.展开更多
文摘Follicle-stimulating hormone (FSH) plays a central role in mammals reproduction, with the actions of FSH mediated by follicle-stimulating hormone receptors (FSHRs) on the surface of target cells. The purposes of this study were to determine and evaluate the biological activities for the commercialization of recombinant follicle-stimulating hormone (rFSH) in vitro through the cellular internalization using cloned 293T-FSHR cell lines as target. Using imaging approaches we have found here that a little fluorescent signal from the surface of the cell transferred to the cytoplasm and accumulated around the nucleus by endocytosis. Compared with the control groups, the commercialization of rFSH have not the significant differences of internalization, but the rFSH have promoted the internalization of the fluorescent, suggested that this detection system might as a protocol for the bioactivity of recombinant therapeutic proteins in vitro.
文摘Objective To investigate the difference in the outcome of IVF-ET between the patients using recombinant FSH versus highly purified urinary FSH for controlled ovarian stimulation （COH）. Methods A comparative retrospective analysis was performed between the patients undergoing IVF using recombinant FSH （rFSH） 562 cycles （rFSH group） versus using highly purified urinary FSH（uFSH） 555 cycles （uFSH group） for COH from August 2009 to July 2010. Main outcome measures included： duration of stimulation, total amount of FSH, E2 level on hCG injection day, number of oocytes collected, average number of frozen embryos, and the rate of cancellation, implantation, clinical pregnancy and miscarriage rate. Results uFSH group required a significantly higher total amount of FSH and a longer duration of stimulation than thouse rFSH group （19.3 ± 7.6 vs 18.3 ± 7.0 ampoules, P=0.02, and 9.1 ± 1.6 d vs 8.9 ± 1.5 d, P=0.04, respectively）. There was no statistically significant difference in the implantation rate, clinical pregnancy rate and miscarriage rate between uFSH and rFSH groups （22.57% vs 20.16%, 38.15% vs 35.18%, and 10.6% vs 13.45%, respectively, P〉0.05）. The other measures including E2 level on hCG injection day, cancellation, number of oocytes collected, fertilization, average number of frozen embryos showed no difference between the two groups. Conclusion There is no significant difference in the outcome of IVF-ET between two groups in effects of recombinant FSH versus highly purified urinary FSH for COH.
